Join us for the 8th Annual Hematologic Malignancies Symposium and Genomics Workshop

Join leading clinicians, researchers, and industry experts for the 8th Annual Hematologic Malignancies Symposium & Genomics Workshop — a two-day meeting exploring the future of blood cancer care through the lens of genomics, artificial intelligence, and health equity.

This year’s program features in-depth sessions on racial and ethnic disparities in malignant hematology, AI and computational biology in AML and MDS, and translational updates across myeloid, lymphoid, and myeloma malignancies. Through expert lectures, panel discussions, and interactive case presentations, attendees will gain practical insights into the science shaping tomorrow’s precision therapies.

Continuing education credit (CME/CE/MOC) will be available — details to follow.

Don’t miss this opportunity to connect with peers and pioneers advancing innovation and equity in hematologic oncology.

Registration opens soon.

The Event

May 7-8, 2026

8th Annual Hematologic Malignancies Symposium and Genomics Workshop

JW Marriott Water Street
510 Water Street
Tampa, FL 33602

In Person Event

Prices

Vendor/Technology Provider

$359

Academic/Government/Non-Profit/General Attendee

$99

Student/Fellow

Steering Committee

Jennifer Varca
President
Genomic Testing Cooperative
View Profile
President
Genomic Testing Cooperative
Jennifer Varca oversees business development strategy, Co-Op member recruitment, and joint venture partnerships for Genomic Testing Coopertive (GTC), bringing extensive commercial leadership experience across the diagnostics and home healthcare industries.
Before joining GTC, Jennifer led sales for the Health Systems Division of Quest Diagnostics Nichols Institute, where she focused on advanced diagnostics and played a key role in shaping the region’s strategic growth initiatives.
Earlier in her career, she spent more than a decade as a Senior Executive at Maxim Healthcare Services, overseeing business development and the continuum of care for skilled nursing and home health programs nationwide.
Jennifer earned her Bachelor of Arts in Communications from California Polytechnic State University, San Luis Obispo, where she was a four-year member of the Women’s Division I Soccer Team.
Maher Albitar, MD
Founder
Chief Executive Officer
Chief Medical Officer
Genomic Testing Cooperative
View Profile
Founder
Chief Executive Officer
Chief Medical Officer
Genomic Testing Cooperative
Dr. Albitar has extensive experience in anatomic/clinical pathology, hematopathology, and molecular pathology. He also has extensive business and administrative experience as an executive leader of large laboratories, Board member, and director of large scientific and genomic diagnostic studies. Until recently, Dr. Albitar was the Senior Vice President, Chief Medical Officer and Director of Research and Development at NeoGenomics.
He is credited with transforming the NeoGenomics Laboratories from FISH testing company to a company offering the most sophisticated molecular testing. Prior to NeoGenomics, Dr. Albitar served as the Medical Director for Hematopathology and Oncology, Nichols Institute, Quest Diagnostics, and Chief R&D for Hematopathology and Oncology for Quest Diagnostics from 2003 to 2010. From 1991 to 2003, Dr. Albitar held various faculty positions at the University of Texas MD Anderson Cancer Center, including Section Chief of Leukemia Section in Laboratory Medicine and Pathology Department, Director of the molecular laboratory and Director of Hematopathology Fellowship program.
Dr. Albitar was a tenured full professor in Pathology and Leukemia at the time of leaving MD Anderson Cancer Center. Dr. Albitar is certified AP/CP pathologist with fellowship training in Hematopathology and molecular pathology. After his training in Hematopathology, Dr. Albitar spent 4 years in Physician/Scientist training program at the University of Pennsylvania/Howard Hughes Medical Institute and the Department of Genetics. Dr. Albitar has published more than 300 peer-reviewed papers, book chapters, and review articles. He is the lead inventor on more than 50 different patents and patent applications.
Gustavo Rivero, MD
Director, Translational Research for Hematologic Malignancies
Tampa General Hospital Cancer Institute
View Profile
Director
Translational Research for Hematologic Malignancies
Tampa General Hospital Cancer Institute
Dr. Rivero is a hematologist oncologist and translational scientist at Tampa General Hospital. Prior to joining Tampa General, he served as an associate professor in hematology and oncology at Baylor College of Medicine and Georgetown University School of Medicine. A distinguished translational scientist, Dr. Rivero focuses on advancing treatments for myeloid malignancies, including Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myeloproliferative Neoplasms (MPN).
Dr. Rivero’s research is not just about understanding the mechanisms that initiate leukemia, but also about pushing the boundaries of what is possible. His recent discovery of a novel age-related nucleotide modification prevalent in AML is a testament to his commitment to innovation. Dr. Rivero’s team is also investigating how leukemia induces immunogenicity to develop innovative cellular and vaccine-based treatments to prevent and combat these disorders.
Dr. Rivero completed his advanced training in hematology and oncology at the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH) in Bethesda, Maryland.
His board certifications include Internal Medicine and Hematology. He earned his medical degree from Francisco de Miranda University in Coro, Venezuela, and completed his internship and residency at J. Stroger Hospital of Cook County in Chicago, Illinois.
Eduardo Sotomayor, MD
Executive Director
Tampa General Hospital Cancer Institute
View Profile
Executive Director
Tampa General Hospital Cancer Institute
Dr. Sotomayor is the director of the newly established Cancer Institute at Tampa General Hospital. He is a pioneer in the field of cancer immunology and immunotherapy and an internationally renowned expert in lymphoma research and treatment. Prior to joining Tampa General, he was the director of the George Washington University Cancer Center with responsibility and authority over all aspects of cancer care and research at GW and affiliated health systems. He was also a professor of medicine in the division of hematology/oncology at George Washington University School of Medicine and Health Sciences.
Dr. Sotomayor has returned to Tampa, where he previously had a highly productive 15-year tenure with Moffitt Cancer Center. He served as the Susan and John Sykes Endowed Chair of Hematologic Malignancies and chair of the department of malignant hematology. In addition, he was the scientific director of the DeBartolo Family Personalized Medicine Institute at Moffitt Cancer Center. He also guided future medical professionals as a professor in the University of South Florida College of Medicine’s departments of oncologic sciences, and pathology and cell biology.
David Swoboda, MD
Director, Leukemia Program
Tampa General Hospital Cancer Institute
View Profile
Director
Leukemia Program
Tampa General Hospital Cancer Institute
Dr. David Swoboda is a hematologist oncologist at Tampa General Hospital who specializes in malignant hematology. Prior to joining Tampa General, he was a chief hematology-oncology fellow at H. Lee Moffitt Cancer Center in Tampa after serving as a chief resident at Medstar Georgetown University Hospital in Washington, D.C. Dr. Swoboda received his medical degree from Florida State University College of Medicine in Tallahassee, where he was the president of the Internal Medicine Interest Group.
Dr. Swoboda enjoys developing a close relationship with his patients and their families, building trust and gaining a full understanding of each disease in order to provide personalized, comprehensive care. His research is directed toward acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative disorders. He has published several entries in peer-reviewed journals and has participated in numerous scientific abstract presentations. Dr. Swoboda has memberships with the Society for Hematology Oncology, American Society of Hematology and American Society of Clinical Oncology.